Next Article in Journal
Mutations in EMT-Related Genes in ALK Positive Crizotinib Resistant Non-Small Cell Lung Cancers
Next Article in Special Issue
Locally Advanced Pancreatic Cancer: A Review of Local Ablative Therapies
Previous Article in Journal
Current Advances in Aptamers for Cancer Diagnosis and Therapy
Previous Article in Special Issue
Lipid Metabolism and Lipid Droplets in Pancreatic Cancer and Stellate Cells
Open AccessEditor’s ChoiceReview

Immune Evasion in Pancreatic Cancer: From Mechanisms to Therapy

Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM), Barcelona 08003, Spain
Institute of Biomedical Research of Barcelona (IIBB-CSIC), Barcelona 08036, Spain
Author to whom correspondence should be addressed.
Cancers 2018, 10(1), 6;
Received: 1 December 2017 / Revised: 22 December 2017 / Accepted: 27 December 2017 / Published: 3 January 2018
(This article belongs to the Special Issue Latest Development in Pancreatic Cancer)
Pancreatic ductal adenocarcinoma (PDA), the most frequent type of pancreatic cancer, remains one of the most challenging problems for the biomedical and clinical fields, with abysmal survival rates and poor therapy efficiency. Desmoplasia, which is abundant in PDA, can be blamed for much of the mechanisms behind poor drug performance, as it is the main source of the cytokines and chemokines that orchestrate rapid and silent tumor progression to allow tumor cells to be isolated into an extensive fibrotic reaction, which results in inefficient drug delivery. However, since immunotherapy was proclaimed as the breakthrough of the year in 2013, the focus on the stroma of pancreatic cancer has interestingly moved from activated fibroblasts to the immune compartment, trying to understand the immunosuppressive factors that play a part in the strong immune evasion that characterizes PDA. The PDA microenvironment is highly immunosuppressive and is basically composed of T regulatory cells (Tregs), tumor-associated macrophages (TAMs), and myeloid-derived suppressive cells (MDSCs), which block CD8+ T-cell duties in tumor recognition and clearance. Interestingly, preclinical data have highlighted the importance of this immune evasion as the source of resistance to single checkpoint immunotherapies and cancer vaccines and point at pathways that inhibit the immune attack as a key to solve the therapy puzzle. Here, we will discuss the molecular mechanisms involved in PDA immune escape as well as the state of the art of the PDA immunotherapy. View Full-Text
Keywords: pancreatic cancer; immune surveillance; galectins; immunotherapy; immune checkpoints; stroma pancreatic cancer; immune surveillance; galectins; immunotherapy; immune checkpoints; stroma
Show Figures

Figure 1

MDPI and ACS Style

Martinez-Bosch, N.; Vinaixa, J.; Navarro, P. Immune Evasion in Pancreatic Cancer: From Mechanisms to Therapy. Cancers 2018, 10, 6.

AMA Style

Martinez-Bosch N, Vinaixa J, Navarro P. Immune Evasion in Pancreatic Cancer: From Mechanisms to Therapy. Cancers. 2018; 10(1):6.

Chicago/Turabian Style

Martinez-Bosch, Neus; Vinaixa, Judith; Navarro, Pilar. 2018. "Immune Evasion in Pancreatic Cancer: From Mechanisms to Therapy" Cancers 10, no. 1: 6.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop